Oncovista

latest news

AndaGen AG Completes Successful Financial Restructuring

Eliminates over four million Euros in debt from balance sheet

San Antonio, Texas and Hanover, Germany - May 4, 2009 - AdnaGen AG announced today the completion of its debt restructuring efforts.

AdnaGen AG, developer and marketer of blood test diagnostics kits for the identification and molecular analysis of circulating tumor cells, substantially reduced its debt by exchanging €4.2 million of debt and related accrued interest for equity. This event is a significant milestone in completing the financial turn-around and corporate renewal for AdnaGen. OncoVista, Inc., AdnaGen’s 95% majority shareholder, together with financial investors Technologie-Beteiligungs-Gesellschaft mbH, Mittelstandische Beteilgungsgesellschaft Niedersachsen and Biomed Venture GmbH joined forces to position AdnaGen with the ability to secure additional financing to support the Company’s growth strategy

CTRC and OncoVista Announce Initiation of Collaboration on Clinical Development of OVI-117

Cancer Therapy & Research Center at The University of Texas Health Science Center and OncoVista Innovative Therapies, Inc. Announce the Initiation of Collaboration on the Clinical Development of OVI-117

San Antonio, TX, --- April 7, 2009 – OncoVista Innovative Therapies, Inc. (“OncoVista”) (OTC BB: OVIT.OB) and the Cancer Therapy & Research Center at The University of Texas Health Science Center in San Antonio, (CTRC at UTHSCSA) announced that the CTRC’s Institute for Drug Development will collaborate on early phase studies of OncoVista’s OVI-117, an L-nucleoside conjugate of 5-fluorodeoxyuridine monophosphate (FdUMP), an analog of 5-FU, in various solid tumor cancer indications. This work is in addition to a Phase I/II Study of Cordycepin plus Pentostatin in Patients with Refractory TdT-Positive Leukemia, sponsored by OncoVista that is currently underway at the CTRC.

AdnaGen AG and OncoVista Innovative Therapies Inc., Announce the Issuance in the US of a Key Patent

Related to Technology for the Detection and Analysis of Circulating Tumor Cells

Patent covers core technology for the detection and molecular analysis of rare cells including EMT and cancer stem cells

Langenhagen, Germany; San Antonio, TX, USA, March 26, 2009

AdnaGen AG, a molecular diagnostics company, and subsidiary of OncoVista Inc., (OTCBB:OVIT.OB), focused on the detection and molecular analysis of tumor cells from the blood of cancer patients has been issued a core-patent by the United States Patent and Trademark Office. United States Patent 7,507,528 issued Mar 24, 2009, and titled “Method and Diagnosis Kit for Selecting and or Qualitative and/or Quantitative Detection of Cells”, claims broad methods for the identification and molecular analysis of rare cells, particularly circulating tumor cells, in the presence of a large excess of unrelated cells.

Sysmex to Distribute AdnaGen Kits in Europe

Sysmex Europe GmbH to distribute products for the analysis of circulating tumor cells in different tumor entities developed by AdnaGen AG, a subsidiary of OncoVista Innovative Therapies Inc.

Norderstedt and Langenhagen, Germany, – January 29, 2009 – Sysmex Europe GmbH and AdnaGen AG announced today that they have entered into a non-exclusive European distribution agreement for all current and future AdnaGen proprietary CE-certified diagnostics as well as their research use only (RUO) products. The tests are based on the capture of circulating tumor cells (CTCs) from blood and subsequent detection and profiling of tumor markers.